Skip to main content

Table 2 Patient drug levels and anti-drug antibodies

From: Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA)

  Subgroup analysis with trough levels
Anti TNF, no. of drug levels/no. of patientsa
 Etanercept 21/15 6/6
 Adalimumab 51/38 22/21
 Infliximab 70/28 70/28
Drug levels, median (range / IQR)
 Etanercept 2.4 (0.0–8.1 / 1.8–3) 2.2 (0.9–2.7 / 0.9–2.9)
 Adalimumab 12 (0–49 / 4.8–15) 10.2 (0–27 / 0.01–14)
 Infliximab 16 (0–81 / 7.3–23) 16 (0–81 / 7.3–23)
Therapeutic drug levelsb (% per drug group)
 Etanercept   3 (50%)
 Adalimumab   0 (0%)
 Infliximab   11 (16%)
Subtherapeutic drug levelsb
 Etanercept   2 (33%)
 Adalimumab   9 (41%)
 Infliximab   5 (7%)
Supratherapeutic drug levelsb
 Etanercept   1 (17%)
 Adalimumab   13 (59%)
 Infliximab   53 (77%)
Antidrug antibodies (% of patients using that drug)
 Adalimumab 7 (18.4%)  
 Infliximab 1 (4%)  
  1. a A few patients had received more than one anti-TNF drug on different time points
  2. b according to adult data in RA and IBD; therapeutic drug levels for JIA are not yet determined